Moderna Settles Legal Dispute with $1.3B Liability as Institutional Investors Adjust Holdings
Moderna has settled with Arbutus and Genevant, facing a potential $1.3 billion liability contingent on Federal Circuit's decision. Multiple institutional investors have increased their stakes in the biotech company during recent quarters.
Moderna has reached a settlement with Arbutus and Genevant, which significantly reduces some of the legal challenges facing the company. However, the agreement includes a potential additional payment of up to $1.3 billion, contingent upon the Federal Circuit's final decision on liability.
Founded in 2010, Moderna is a commercial-stage biotechnology company that gained prominence with its mRNA technology, particularly through its COVID-19 vaccine authorized in December 2020. The company has a diverse pipeline with 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Several institutional investors have recently modified their holdings in the company. Guggenheim Strategic Opportunities Fund raised its stake in Moderna by 20.57%, purchasing 123 shares to own 721 shares valued at about $18,730 as of the latest 13F filing. Avantis U.S. Equity ETF raised its stake by 10.6%, purchasing 2,873 shares to own 29,970 shares valued at about $778,620 as of the latest 13F filing.
Other large investors also increased their positions. Global X Genomics & Biotechnology ETF raised its stake by 31.5%, purchasing 19,911 shares to own 83,121 shares valued at about $2,159,480 as of the latest 13F filing. INVESCO EQUALLY-WEIGHTED S&P 500 FUND raised its stake by 16.14%, purchasing 76,152 shares to own 548,037 shares valued at about $14,238,000 as of the latest 13F filing. ProShares UltraPro S&P500 raised its stake by 28.54%, purchasing 3,934 shares to own 17,720 shares valued at about $460,370 as of the latest 13F filing.
Moderna's financial metrics reveal significant challenges. Revenue for the trailing twelve months stands at $1.922 billion, with a three-year growth rate of -52.2%. Operating margin is deeply negative at -159.94%, indicating substantial operational inefficiencies. Net margin is also negative at -146.83%, reflecting ongoing profitability challenges. Gross margin remains positive at 54.84%, but has been declining over the years.
On the balance sheet front, Moderna exhibits a strong liquidity position. Current ratio is 3.29, indicating ample short-term liquidity. Debt-to-equity ratio is low at 0.15, suggesting conservative leverage. Cash ratio is 2.92, further underscoring liquidity strength. The Altman Z-Score of 3.89 indicates strong financial health.
The company has a market capitalization of approximately $19.68 billion. Institutional ownership is robust at 77.94%, while insider ownership stands at 5.97%. Warning signs include a low Piotroski F-Score of 2, indicating poor business operations, and significant insider selling activity with no insider buying in the past three months.